arrow
A

Alexis A. Thompson

University of Pennsylvania
H指数:55
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia
Blood
IF23.1
2026-01-140
OA
Establishing Absolute Neutrophil Count and White Blood Cell Count Reference Intervals for the Duffy Null Population

建立 Duffy 零人群中绝对中性粒细胞计数和白细胞的参考区间

2026-01-010
OAAI
Hospital Variations in Time-To-Crisis-Resolution Among Children and Adolescents With Sickle Cell Disease

儿童和青少年镰状细胞病患者危机解决时间的医院差异

2025-11-050
OAAI
Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Successful Engraftment, Increased Hemoglobin, and Reduced Transfusion Dependence in Patients with Transfusion-Dependent Beta-Thalassemia Treated in the Edithal Trial

Reni-Cel,一种正在研究的AsCas12a基因编辑细胞药物,在Edithal试验中治疗依赖输血的β-地中海贫血患者时,实现了成功植入、增加了血红蛋白含量并降低了输血依赖性。

BLOOD
IF23.1
2024-11-050
PRE
High Concordance between Investigator-Verified Diagnosis and Manual Data Abstraction for Sickle Cell Diagnosis Type: An ASH Research Collaborative Data Hub Validation Study

研究者确认诊断与手动数据提取在镰状细胞病诊断类型方面的高一致性:一项ASH研究协作数据中心的验证研究

BLOOD
IF23.1
2024-11-050
PRE
Outcomes of Immunosuppressive Therapy in Children Less Than Three Years of Age with Idiopathic Severe Aplastic Anemia: A North American Collaboration

小于3岁特发性严重再生障碍性贫血患儿免疫抑制治疗的结局:一项北美合作研究

BLOOD
IF23.1
2024-11-050
PRE
An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel

关于Lovotibeglogene Autotemcel(Lovo-cel)治疗镰状细胞病(SCD)的临床试验进展及对Lovo-cel反应的早期预测因子分析

BLOOD
IF23.1
2024-11-050
PRE
Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial

Betibeglogene autotemcel基因治疗输血依赖性,严重基因型 β-地中海贫血 (HGB-212) 患者: 一项非随机,多中心,单臂,开放标签,单剂量,3期试验

LANCET
IF88.5
2024-11-010
PRE
Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission
2023-08-0141
OAAI